Matrix metalloproteinases in coronary artery disease

Advances in Clinical Chemistry

Volumn 64, Issue , 2014, Pages 1-72

  Mittal, Balraj ^a   Mishra, Avshesh ^a   Srivastava, Anshika ^a   Kumar, Surendra ^a   Garg, Naveen ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Atherosclerosis; Case control association studies; Plaque instability; Tissue inhibitors of metalloproteinases; Vascular remodeling

Indexed keywords

MATRIX METALLOPROTEINASE;

ANGIOGENESIS; ANIMAL; ATHEROSCLEROTIC PLAQUE; CHEMISTRY; CORONARY ARTERY DISEASE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HUMAN; PHYSIOLOGY;

ANIMALS; CORONARY ARTERY DISEASE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MATRIX METALLOPROTEINASES; NEOVASCULARIZATION, PHYSIOLOGIC; PLAQUE, ATHEROSCLEROTIC; POLYMORPHISM, GENETIC;

EID: 84897952053     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-800263-6.00001-X     Document Type: Chapter

References (344)

1. Birkedal-Hansen H. Proteolytic remodeling of extracellular matrix. Curr. Opin. Cell Biol. 1995, 7:728-735.
2. Brauer P.R. MMPs-role in cardiovascular development and disease. Front. Biosci. 2006, 11:447-478.
3. Galis Z.S., Khatri J.J. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ. Res. 2002, 90:251-262.
4. Papageorgiou N., Tousoulis D., Hatzis G., Briasoulis A., Androulakis E., Giolis A., et al. Genetic variability of matrix metalloproteinase genes in cardiovascular disease. Curr. Top. Med. Chem. 2012, 12:1206-1213.
5. Zitka O., Kukacka J., Krizkova S., Huska D., Adam V., Masarik M., et al. Matrix metalloproteinases. Curr. Med. Chem. 2010, 17:3751-3768.
6. Puente X.S., Sanchez L.M., Overall C.M., Lopez-Otin C. Human and mouse proteases: a comparative genomic approach. Nat. Rev. Genet. 2003, 4:544-558.
7. Limb G.A., Matter K., Murphy G., Cambrey A.D., Bishop P.N., Morris G.E., et al. Matrix metalloproteinase-1 associates with intracellular organelles and confers resistance to lamin A/C degradation during apoptosis. Am. J. Pathol. 2005, 166:1555-1563.
8. Kwan J.A., Schulze C.J., Wang W., Leon H., Sariahmetoglu M., Sung M., et al. Matrix metalloproteinase-2 (MMP-2) is present in the nucleus of cardiac myocytes and is capable of cleaving poly (ADP-ribose) polymerase (PARP) in vitro. FASEB J. 2004, 18:690-692.
9. Luo D., Mari B., Stoll I., Anglard P. Alternative splicing and promoter usage generates an intracellular stromelysin 3 isoform directly translated as an active matrix metalloproteinase. J. Biol. Chem. 2002, 277:25527-25536.
10. Bode W., Gomis-Ruth F.X., Stockler W. Astacins, serralysins, snake venom and matrix metalloproteinases exhibit identical zinc-binding environments (HEXXHXXGXXH and Met-turn) and topologies and should be grouped into a common family, the 'metzincins'. FEBS Lett. 1993, 331:134-140.
11. Boire A., Covic L., Agarwal A., Jacques S., Sherifi S., Kuliopulos A. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 2005, 120:303-313.
12. Aimes R.T., Quigley J.P. Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments. J. Biol. Chem. 1995, 270:5872-5876.
13. Patterson M.L., Atkinson S.J., Knauper V., Murphy G. Specific collagenolysis by gelatinase A, MMP-2, is determined by the hemopexin domain and not the fibronectin-like domain. FEBS Lett. 2001, 503:158-162.
14. Murphy G., Segain J.P., O'Shea M., Cockett M., Ioannou C., Lefebvre O., et al. The 28-kDa N-terminal domain of mouse stromelysin-3 has the general properties of a weak metalloproteinase. J. Biol. Chem. 1993, 268:15435-15441.
15. Pei D., Majmudar G., Weiss S.J. Hydrolytic inactivation of a breast carcinoma cell-derived serpin by human stromelysin-3. J. Biol. Chem. 1994, 269:25849-25855.
16. Pei D., Weiss S.J. Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature 1995, 375:244-247.
17. Marchenko N.D., Marchenko G.N., Weinreb R.N., Lindsey J.D., Kyshtoobayeva A., Crawford H.C., et al. Beta-catenin regulates the gene of MMP-26, a novel metalloproteinase expressed both in carcinomas and normal epithelial cells. Int. J. Biochem. Cell Biol. 2004, 36:942-956.
18. English W.R., Puente X.S., Freije J.M., Knauper V., Amour A., Merryweather A., et al. Membrane type 4 matrix metalloproteinase (MMP17) has tumor necrosis factor-alpha convertase activity but does not activate pro-MMP2. J. Biol. Chem. 2000, 275:14046-14055.
19. Ohuchi E., Imai K., Fujii Y., Sato H., Seiki M., Okada Y. Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J. Biol. Chem. 1997, 272:2446-2451.
20. Holmbeck K., Bianco P., Caterina J., Yamada S., Kromer M., Kuznetsov S.A., et al. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 1999, 99:81-92.
21. Kerkela E., Bohling T., Herva R., Uria J.A., Saarialho-Kere U. Human macrophage metalloelastase (MMP-12) expression is induced in chondrocytes during fetal development and malignant transformation. Bone 2001, 29:487-493.
22. Hou P., Troen T., Ovejero M.C., Kirkegaard T., Andersen T.L., Byrjalsen I., et al. Matrix metalloproteinase-12 (MMP-12) in osteoclasts: new lesson on the involvement of MMPs in bone resorption. Bone 2004, 34:37-47.
23. Stracke J.O., Hutton M., Stewart M., Pendas A.M., Smith B., Lopez-Otin C., et al. Biochemical characterization of the catalytic domain of human matrix metalloproteinase 19. Evidence for a role as a potent basement membrane degrading enzyme. J. Biol. Chem. 2000, 275:14809-14816.
24. Ryu O.H., Fincham A.G., Hu C.C., Zhang C., Qian Q., Bartlett J.D., et al. Characterization of recombinant pig enamelysin activity and cleavage of recombinant pig and mouse amelogenins. J. Dent. Res. 1999, 78:743-750.
25. Yang M., Murray M.T., Kurkinen M. A novel matrix metalloproteinase gene (XMMP) encoding vitronectin-like motifs is transiently expressed in Xenopus laevis early embryo development. J. Biol. Chem. 1997, 272:13527-13533.
26. Marchenko G.N., Marchenko N.D., Strongin A.Y. The structure and regulation of the human and mouse matrix metalloproteinase-21 gene and protein. Biochem. J. 2003, 372:503-515.
27. Ahokas K., Lohi J., Illman S.A., Llano E., Elomaa O., Impola U., et al. Matrix metalloproteinase-21 is expressed epithelially during development and in cancer and is up-regulated by transforming growth factor-beta1 in keratinocytes. Lab Invest. 2003, 83:1887-1899.
28. Velasco G., Pendas A.M., Fueyo A., Knauper V., Murphy G., Lopez-Otin C. Cloning and characterization of human MMP-23, a new matrix metalloproteinase predominantly expressed in reproductive tissues and lacking conserved domains in other family members. J. Biol. Chem. 1999, 274:4570-4576.
29. Pei D., Kang T., Qi H. Cysteine array matrix metalloproteinase (CA-MMP)/MMP-23 is a type II transmembrane matrix metalloproteinase regulated by a single cleavage for both secretion and activation. J. Biol. Chem. 2000, 275:33988-33997.
30. Yang M., Kurkinen M. Cloning and characterization of a novel matrix metalloproteinase (MMP), CMMP, from chicken embryo fibroblasts. CMMP, Xenopus XMMP, and human MMP19 have a conserved unique cysteine in the catalytic domain. J. Biol. Chem. 1998, 273:17893-17900.
31. Saarialho-Kere U., Kerkela E., Jahkola T., Suomela S., Keski-Oja J., Lohi J. Epilysin (MMP-28) expression is associated with cell proliferation during epithelial repair. J Invest Dermatol. 2002, 119:14-21.
32. Seals D.F., Courtneidge S.A. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev. 2003, 17:7-30.
33. Ra H.J., Parks W.C. Control of matrix metalloproteinase catalytic activity. Matrix Biol. 2007, 26:587-596.
34. Overall C.M. Molecular determinants of metalloproteinase substrate specificity: matrix metalloproteinase substrate binding domains, modules, and exosites. Mol. Biotechnol. 2002, 22:51-86.
35. Gearing A.J., Beckett P., Christodoulou M., Churchill M., Clements J., Davidson A.H., et al. Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature 1994, 370:555-557.
36. Levi E., Fridman R., Miao H.Q., Ma Y.S., Yayon A., Vlodavsky I. Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:7069-7074.
37. Ugwu F., Van Hoef B., Bini A., Collen D., Lijnen H.R. Proteolytic cleavage of urokinase-type plasminogen activator by stromelysin-1 (MMP-3). Biochemistry 1998, 37:7231-7236.
38. Lijnen H.R., Ugwu F., Bini A., Collen D. Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3). Biochemistry 1998, 37:4699-4702.
39. Fernandez-Patron C., Radomski M.W., Davidge S.T. Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ. Res. 1999, 85:906-911.
40. Galis Z.S., Muszynski M., Sukhova G.K., Simon-Morrissey E., Unemori E.N., Lark M.W., et al. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ. Res. 1994, 75:181-189.
41. Hanemaaijer R., Koolwijk P., le Clercq L., de Vree W.J., van Hinsbergh V.W. Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells. Effects of tumour necrosis factor alpha, interleukin 1 and phorbol ester. Biochem. J. 1993, 296(Pt. 3):803-809.
42. Galis Z.S., Sukhova G.K., Libby P. Microscopic localization of active proteases by in situ zymography: detection of matrix metalloproteinase activity in vascular tissue. FASEB J. 1995, 9:974-980.
43. Galis Z.S., Sukhova G.K., Lark M.W., Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest. 1994, 94:2493-2503.
44. Benbow U., Brinckerhoff C.E. The AP-1 site and MMP gene regulation: what is all the fuss about?. Matrix Biol. 1997, 15:519-526.
45. Lalu M.M., Pasini E., Schulze C.J., Ferrari-Vivaldi M., Ferrari-Vivaldi G., Bachetti T., et al. Ischaemia-reperfusion injury activates matrix metalloproteinases in the human heart. Eur. Heart J. 2005, 26:27-35.
46. Matrisian L.M. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet. 1990, 6:121-125.
47. Czuwara-Ladykowska J., Sementchenko V.I., Watson D.K., Trojanowska M. Ets1 is an effector of the transforming growth factor beta (TGF-beta) signaling pathway and an antagonist of the profibrotic effects of TGF-beta. J. Biol. Chem. 2002, 277:20399-20408.
48. Hall M.C., Young D.A., Waters J.G., Rowan A.D., Chantry A., Edwards D.R., et al. The comparative role of activator protein 1 and Smad factors in the regulation of Timp-1 and MMP-1 gene expression by transforming growth factor-beta 1. J. Biol. Chem. 2003, 278:10304-10313.
49. Lohi J., Lehti K., Valtanen H., Parks W.C., Keski-Oja J. Structural analysis and promoter characterization of the human membrane-type matrix metalloproteinase-1 (MT1-MMP) gene. Gene 2000, 242:75-86.
50. Uria J.A., Jimenez M.G., Balbin M., Freije J.M., Lopez-Otin C. Differential effects of transforming growth factor-beta on the expression of collagenase-1 and collagenase-3 in human fibroblasts. J. Biol. Chem. 1998, 273:9769-9777.
51. Ogawa K., Chen F., Kuang C., Chen Y. Suppression of matrix metalloproteinase-9 transcription by transforming growth factor-beta is mediated by a nuclear factor-kappaB site. Biochem. J. 2004, 381:413-422.
52. Vincenti M.P. The matrix metalloproteinase (MMP) and tissue inhibitor of metalloproteinase (TIMP) genes. Transcriptional and posttranscriptional regulation, signal transduction and cell-type-specific expression. Methods Mol. Biol. 2001, 151:121-148.
53. Souslova V., Townsend P.A., Mann J., van der Loos C.M., Motterle A., D'Acquisto F., et al. Allele-specific regulation of matrix metalloproteinase-3 gene by transcription factor NFkappaB. PLoS One 2010, 5:e9902.
54. Fu X., Kao J.L., Bergt C., Kassim S.Y., Huq N.P., d'Avignon A., et al. Oxidative cross-linking of tryptophan to glycine restrains matrix metalloproteinase activity: specific structural motifs control protein oxidation. J. Biol. Chem. 2004, 279:6209-6212.
55. Gu Z., Kaul M., Yan B., Kridel S.J., Cui J., Strongin A., et al. S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science 2002, 297:1186-1190.
56. Liu W., Rosenberg G.A., Shi H., Furuichi T., Timmins G.S., Cunningham L.A., et al. Xanthine oxidase activates pro-matrix metalloproteinase-2 in cultured rat vascular smooth muscle cells through non-free radical mechanisms. Arch. Biochem. Biophys. 2004, 426:11-17.
57. Yoon S.O., Park S.J., Yoon S.Y., Yun C.H., Chung A.S. Sustained production of H(2)O(2) activates pro-matrix metalloproteinase-2 through receptor tyrosine kinases/phosphatidylinositol 3-kinase/NF-kappa B pathway. J. Biol. Chem. 2002, 277:30271-30282.
58. Fu X., Kassim S.Y., Parks W.C., Heinecke J.W. Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J. Biol. Chem. 2001, 276:41279-41287.
59. Mathy-Hartert M., Bourgeois E., Grulke S., Deby-Dupont G., Caudron I., Deby C., et al. Purification of myeloperoxidase from equine polymorphonuclear leucocytes. Can. J. Vet. Res. 1998, 62:127-132.
60. Wang W., Sawicki G., Schulz R. Peroxynitrite-induced myocardial injury is mediated through matrix metalloproteinase-2. Cardiovasc. Res. 2002, 53:165-174.
61. Osenkowski P., Toth M., Fridman R. Processing, shedding, and endocytosis of membrane type 1-matrix metalloproteinase (MT1-MMP). J. Cell. Physiol. 2004, 200:2-10.
62. Pavlaki M., Cao J., Hymowitz M., Chen W.T., Bahou W., Zucker S. A conserved sequence within the propeptide domain of membrane type 1 matrix metalloproteinase is critical for function as an intramolecular chaperone. J. Biol. Chem. 2002, 277:2740-2749.
63. Remacle A., Murphy G., Roghi C. Membrane type I-matrix metalloproteinase (MT1-MMP) is internalised by two different pathways and is recycled to the cell surface. J. Cell Sci. 2003, 116:3905-3916.
64. Stawowy P., Meyborg H., Stibenz D., Borges Pereira Stawowy N., Roser M., Thanabalasingam U., et al. Furin-like proprotein convertases are central regulators of the membrane type matrix metalloproteinase-pro-matrix metalloproteinase-2 proteolytic cascade in atherosclerosis. Circulation 2005, 111:2820-2827.
65. Remacle A.G., Rozanov D.V., Baciu P.C., Chekanov A.V., Golubkov V.S., Strongin A.Y. The transmembrane domain is essential for the microtubular trafficking of membrane type-1 matrix metalloproteinase (MT1-MMP). J. Cell Sci. 2005, 118:4975-4984.
66. Koziol A., Martin-Alonso M., Clemente C., Gonzalo P., Arroyo A.G. Site-specific cellular functions of MT1-MMP. Eur. J. Cell Biol. 2012, 91:889-895.
67. Brew K., Dinakarpandian D., Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim. Biophys. Acta 2000, 1477:267-283.
68. Cawston T.E., Curry V.A., Clark I.M., Hazleman B.L. Identification of a new metalloproteinase inhibitor that forms tight-binding complexes with collagenase. Biochem. J. 1990, 269:183-187.
69. Nagase H., Visse R., Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc. Res. 2006, 69:562-573.
70. Strongin A.Y., Marmer B.L., Grant G.A., Goldberg G.I. Plasma membrane-dependent activation of the 72-kDa type IV collagenase is prevented by complex formation with TIMP-2. J. Biol. Chem. 1993, 268:14033-14039.
71. Denhardt D.T., Feng B., Edwards D.R., Cocuzzi E.T., Malyankar U.M. Tissue inhibitor of metalloproteinases (TIMP, aka EPA): structure, control of expression and biological functions. Pharmacol. Ther. 1993, 59:329-341.
72. Pavloff N., Staskus P.W., Kishnani N.S., Hawkes S.P. A new inhibitor of metalloproteinases from chicken: ChIMP-3. A third member of the TIMP family. J. Biol. Chem. 1992, 267:17321-17326.
73. Yang T.T., Hawkes S.P. Role of the 21-kDa protein TIMP-3 in oncogenic transformation of cultured chicken embryo fibroblasts. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:10676-10680.
74. Amour A., Slocombe P.M., Webster A., Butler M., Knight C.G., Smith B.J., et al. TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett. 1998, 435:39-44.
75. Schlondorff J., Blobel C.P. Metalloprotease-disintegrins: modular proteins capable of promoting cell-cell interactions and triggering signals by protein-ectodomain shedding. J. Cell Sci. 1999, 112(Pt. 21):3603-3617.
76. Greene J., Wang M., Liu Y.E., Raymond L.A., Rosen C., Shi Y.E. Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J. Biol. Chem. 1996, 271:30375-30380.
77. Liu Y.E., Wang M., Greene J., Su J., Ullrich S., Li H., et al. Preparation and characterization of recombinant tissue inhibitor of metalloproteinase 4 (TIMP-4). J. Biol. Chem. 1997, 272:20479-20483.
78. Stratmann B., Farr M., Tschesche H. MMP-TIMP interaction depends on residue 2 in TIMP-4. FEBS Lett. 2001, 507:285-287.
79. Chen X., Wang J., Zhou F., Wang X., Feng Z. STAT proteins mediate angiotensin II-induced production of TIMP-1 in human proximal tubular epithelial cells. Kidney Int. 2003, 64:459-467.
80. Hammani K., Blakis A., Morsette D., Bowcock A.M., Schmutte C., Henriet P., et al. Structure and characterization of the human tissue inhibitor of metalloproteinases-2 gene. J. Biol. Chem. 1996, 271:25498-25505.
81. De Clerck Y.A., Darville M.I., Eeckhout Y., Rousseau G.G. Characterization of the promoter of the gene encoding human tissue inhibitor of metalloproteinases-2 (TIMP-2). Gene 1994, 139:185-191.
82. Apte S.S., Olsen B.R., Murphy G. The gene structure of tissue inhibitor of metalloproteinases (TIMP)-3 and its inhibitory activities define the distinct TIMP gene family. J. Biol. Chem. 1996, 271:2874.
83. Wick M., Haronen R., Mumberg D., Burger C., Olsen B.R., Budarf M.L., et al. Structure of the human TIMP-3 gene and its cell cycle-regulated promoter. Biochem. J. 1995, 311(Pt. 2):549-554.
84. Kinoshita T., Sato H., Okada A., Ohuchi E., Imai K., Okada Y., et al. TIMP-2 promotes activation of progelatinase A by membrane-type 1 matrix metalloproteinase immobilized on agarose beads. J. Biol. Chem. 1998, 273:16098-16103.
85. Butler G.S., Butler M.J., Atkinson S.J., Will H., Tamura T., Schade van Westrum S., et al. The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A. A kinetic study. J. Biol. Chem. 1998, 273:871-880.
86. Strongin A.Y., Collier I., Bannikov G., Marmer B.L., Grant G.A., Goldberg G.I. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J. Biol. Chem. 1995, 270:5331-5338.
87. Murphy G., Stanton H., Cowell S., Butler G., Knauper V., Atkinson S., et al. Mechanisms for pro matrix metalloproteinase activation. APMIS 1999, 107:38-44.
88. Kleiner D.E., Unsworth E.J., Krutzsch H.C., Stetler-Stevenson W.G. Higher-order complex formation between the 72-kilodalton type IV collagenase and tissue inhibitor of metalloproteinases-2. Biochemistry 1992, 31:1665-1672.
89. Bigg H.F., Morrison C.J., Butler G.S., Bogoyevitch M.A., Wang Z., Soloway P.D., et al. Tissue inhibitor of metalloproteinases-4 inhibits but does not support the activation of gelatinase A via efficient inhibition of membrane type 1-matrix metalloproteinase. Cancer Res. 2001, 61:3610-3618.
90. Poole T.J., Coffin J.D. Vasculogenesis and angiogenesis: two distinct morphogenetic mechanisms establish embryonic vascular pattern. J. Exp. Zool. 1989, 251:224-231.
91. Ferrara N., Carver-Moore K., Chen H., Dowd M., Lu L., O'Shea K.S., et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996, 380:439-442.
92. Carmeliet P., Ferreira V., Breier G., Pollefeyt S., Kieckens L., Gertsenstein M., et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996, 380:435-439.
93. Fong G.H., Rossant J., Gertsenstein M., Breitman M.L. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995, 376:66-70.
94. Shalaby F., Rossant J., Yamaguchi T.P., Gertsenstein M., Wu X.F., Breitman M.L., et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995, 376:62-66.
95. Fowlkes J.L., Serra D.M., Bunn R.C., Thrailkill K.M., Enghild J.J., Nagase H. Regulation of insulin-like growth factor (IGF)-I action by matrix metalloproteinase-3 involves selective disruption of IGF-I/IGF-binding protein-3 complexes. Endocrinology 2004, 145:620-626.
96. Belotti D., Paganoni P., Manenti L., Garofalo A., Marchini S., Taraboletti G., et al. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res. 2003, 63:5224-5229.
97. Anteby E.Y., Greenfield C., Natanson-Yaron S., Goldman-Wohl D., Hamani Y., Khudyak V., et al. Vascular endothelial growth factor, epidermal growth factor and fibroblast growth factor-4 and -10 stimulate trophoblast plasminogen activator system and metalloproteinase-9. Mol. Hum. Reprod. 2004, 10:229-235.
98. Udayakumar T.S., Nagle R.B., Bowden G.T. Fibroblast growth factor-1 transcriptionally induces membrane type-1 matrix metalloproteinase expression in prostate carcinoma cell line. Prostate 2004, 58:66-75.
99. Lamoreaux W.J., Fitzgerald M.E., Reiner A., Hasty K.A., Charles S.T. Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. Microvasc. Res. 1998, 55:29-42.
100. Vu T.H., Shipley J.M., Bergers G., Berger J.E., Helms J.A., Hanahan D., et al. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 1998, 93:411-422.
101. Folkman J., Shing Y. Angiogenesis. J. Biol. Chem. 1992, 267:10931-10934.
102. Seandel M., Noack-Kunnmann K., Zhu D., Aimes R.T., Quigley J.P. Growth factor-induced angiogenesis in vivo requires specific cleavage of fibrillar type I collagen. Blood 2001, 97:2323-2332.
103. Bajou K., Noel A., Gerard R.D., Masson V., Brunner N., Holst-Hansen C., et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat. Med. 1998, 4:923-928.
104. Thurston G., Suri C., Smith K., McClain J., Sato T.N., Yancopoulos G.D., et al. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 1999, 286:2511-2514.
105. Kim I., Kim H.G., Moon S.O., Chae S.W., So J.N., Koh K.N., et al. Angiopoietin-1 induces endothelial cell sprouting through the activation of focal adhesion kinase and plasmin secretion. Circ. Res. 2000, 86:952-959.
106. Murai K.K., Pasquale E.B. 'Eph'ective signaling: forward, reverse and crosstalk. J. Cell Sci. 2003, 116:2823-2832.
107. Himanen J.P., Nikolov D.B. Eph signaling: a structural view. Trends Neurosci. 2003, 26:46-51.
108. Adams R.H. Molecular control of arterial-venous blood vessel identity. J. Anat. 2003, 202:105-112.
109. Gerety S.S., Wang H.U., Chen Z.F., Anderson D.J. Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development. Mol. Cell 1999, 4:403-414.
110. Adams R.H., Wilkinson G.A., Weiss C., Diella F., Gale N.W., Deutsch U., et al. Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. Genes Dev. 1999, 13:295-306.
111. Steinle J.J., Meininger C.J., Forough R., Wu G., Wu M.H., Granger H.J. Eph B4 receptor signaling mediates endothelial cell migration and proliferation via the phosphatidylinositol 3-kinase pathway. J. Biol. Chem. 2002, 277:43830-43835.
112. Gerety S.S., Anderson D.J. Cardiovascular ephrinB2 function is essential for embryonic angiogenesis. Development 2002, 129:1397-1410.
113. Cowan C.A., Yokoyama N., Saxena A., Chumley M.J., Silvany R.E., Baker L.A., et al. Ephrin-B2 reverse signaling is required for axon pathfinding and cardiac valve formation but not early vascular development. Dev. Biol. 2004, 271:263-271.
114. Adams R.H., Diella F., Hennig S., Helmbacher F., Deutsch U., Klein R. The cytoplasmic domain of the ligand ephrinB2 is required for vascular morphogenesis but not cranial neural crest migration. Cell 2001, 104:57-69.
115. Cai D.H., Vollberg T.M., Hahn-Dantona E., Quigley J.P., Brauer P.R. MMP-2 expression during early avian cardiac and neural crest morphogenesis. Anat. Rec. 2000, 259:168-179.
116. Linask K.K., Han M., Cai D.H., Brauer P.R., Maisastry S.M. Cardiac morphogenesis: matrix metalloproteinase coordination of cellular mechanisms underlying heart tube formation and directionality of looping. Dev. Dyn. 2005, 233:739-753.
117. Brauer P.R., Cai D.H. Expression of tissue inhibitor of metalloproteinases (TIMPs) during early cardiac development. Mech. Dev. 2002, 113:175-179.
118. Mjaatvedt C.H., Nakaoka T., Moreno-Rodriguez R., Norris R.A., Kern M.J., Eisenberg C.A., et al. The outflow tract of the heart is recruited from a novel heart-forming field. Dev. Biol. 2001, 238:97-109.
119. Waldo K.L., Kumiski D.H., Wallis K.T., Stadt H.A., Hutson M.R., Platt D.H., et al. Conotruncal myocardium arises from a secondary heart field. Development 2001, 128:3179-3188.
120. Creazzo T.L., Godt R.E., Leatherbury L., Conway S.J., Kirby M.L. Role of cardiac neural crest cells in cardiovascular development. Annu. Rev. Physiol. 1998, 60:267-286.
121. Alexander S.M., Jackson K.J., Bushnell K.M., McGuire P.G. Spatial and temporal expression of the 72-kDa type IV collagenase (MMP-2) correlates with development and differentiation of valves in the embryonic avian heart. Dev. Dyn. 1997, 209:261-268.
122. Song W., Jackson K., McGuire P.G. Degradation of type IV collagen by matrix metalloproteinases is an important step in the epithelial-mesenchymal transformation of the endocardial cushions. Dev. Biol. 2000, 227:606-617.
123. Enciso J.M., Gratzinger D., Camenisch T.D., Canosa S., Pinter E., Madri J.A. Elevated glucose inhibits VEGF-A-mediated endocardial cushion formation: modulation by PECAM-1 and MMP-2. J. Cell Biol. 2003, 160:605-615.
124. Kirby M.L., Waldo K.L. Neural crest and cardiovascular patterning. Circ. Res. 1995, 77:211-215.
125. Duong T.D., Erickson C.A. MMP-2 plays an essential role in producing epithelial-mesenchymal transformations in the avian embryo. Dev. Dyn. 2004, 229:42-53.
126. Cai D.H., Brauer P.R. Synthetic matrix metalloproteinase inhibitor decreases early cardiac neural crest migration in chicken embryos. Dev. Dyn. 2002, 224:441-449.
127. Schatteman G.C., Motley S.T., Effmann E.L., Bowen-Pope D.F. Platelet-derived growth factor receptor alpha subunit deleted Patch mouse exhibits severe cardiovascular dysmorphogenesis. Teratology 1995, 51:351-366.
128. Morrison-Graham K., Schatteman G.C., Bork T., Bowen-Pope D.F., Weston J.A. A PDGF receptor mutation in the mouse (Patch) perturbs the development of a non-neuronal subset of neural crest-derived cells. Development 1992, 115:133-142.
129. Robbins J.R., McGuire P.G., Wehrle-Haller B., Rogers S.L. Diminished matrix metalloproteinase 2 (MMP-2) in ectomesenchyme-derived tissues of the Patch mutant mouse: regulation of MMP-2 by PDGF and effects on mesenchymal cell migration. Dev. Biol. 1999, 212:255-263.
130. Ratajska A., Cleutjens J.P. Embryogenesis of the rat heart: the expression of collagenases. Basic Res. Cardiol. 2002, 97:189-197.
131. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
132. Libby P., Lee R.T. Matrix matters. Circulation 2000, 102:1874-1876.
133. Li Z., Li L., Zielke H.R., Cheng L., Xiao R., Crow M.T., et al. Increased expression of 72-kd type IV collagenase (MMP-2) in human aortic atherosclerotic lesions. Am. J. Pathol. 1996, 148:121-128.
134. Nikkari S.T., O'Brien K.D., Ferguson M., Hatsukami T., Welgus H.G., Alpers C.E., et al. Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis. Circulation 1995, 92:1393-1398.
135. Brown D.L., Hibbs M.S., Kearney M., Loushin C., Isner J.M. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation 1995, 91:2125-2131.
136. Jeng A.Y., Chou M., Sawyer W.K., Caplan S.L., Von Linden-Reed J., Jeune M., et al. Enhanced expression of matrix metalloproteinase-3, -12, and -13 mRNAs in the aortas of apolipoprotein E-deficient mice with advanced atherosclerosis. Ann. N. Y. Acad. Sci. 1999, 878:555-558.
137. Zaltsman A.B., Newby A.C. Increased secretion of gelatinases A and B from the aortas of cholesterol fed rabbits: relationship to lesion severity. Atherosclerosis 1997, 130:61-70.
138. Galis Z.S., Sukhova G.K., Kranzhofer R., Clark S., Libby P. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:402-406.
139. Blankenberg S., Rupprecht H.J., Poirier O., Bickel C., Smieja M., Hafner G., et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003, 107:1579-1585.
140. Agewall S. Matrix metalloproteinases and cardiovascular disease. Eur. Heart J. 2006, 27:121-122.
141. Ikeda U., Takahashi M., Shimada K. Monocyte-endothelial cell interaction in atherogenesis and thrombosis. Clin. Cardiol. 1998, 21:11-14.
142. Lijnen H.R., Van Hoef B., Lupu F., Moons L., Carmeliet P., Collen D. Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes. Arterioscler. Thromb. Vasc. Biol. 1998, 18:1035-1045.
143. Lijnen H.R., Soloway P., Collen D. Tissue inhibitor of matrix metalloproteinases-1 impairs arterial neointima formation after vascular injury in mice. Circ. Res. 1999, 85:1186-1191.
144. Shah P.K., Falk E., Badimon J.J., Fernandez-Ortiz A., Mailhac A., Villareal-Levy G., et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 1995, 92:1565-1569.
145. Choudhary S., Higgins C.L., Chen I.Y., Reardon M., Lawrie G., Vick G.W., et al. Quantitation and localization of matrix metalloproteinases and their inhibitors in human carotid endarterectomy tissues. Arterioscler. Thromb. Vasc. Biol. 2006, 26:2351-2358.
146. Henney A.M., Wakeley P.R., Davies M.J., Foster K., Hembry R., Murphy G., et al. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc. Natl. Acad. Sci. U.S.A. 1991, 88:8154-8158.
147. Galis Z.S., Muszynski M., Sukhova G.K., Simon-Morrissey E., Libby P. Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions. Ann. N. Y. Acad. Sci. 1995, 748:501-507.
148. Halpert I., Sires U.I., Roby J.D., Potter-Perigo S., Wight T.N., Shapiro S.D., et al. Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:9748-9753.
149. Pasterkamp G., Schoneveld A.H., Hijnen D.J., de Kleijn D.P., Teepen H., van der Wal A.C., et al. Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteases 1, 2 and 9 in the human coronary artery. Atherosclerosis 2000, 150:245-253.
150. Ye S., Humphries S., Henney A. Matrix metalloproteinases: implication in vascular matrix remodelling during atherogenesis. Clin. Sci. (Lond.) 1998, 94:103-110.
151. Liang J., Liu E., Yu Y., Kitajima S., Koike T., Jin Y., et al. Macrophage metalloelastase accelerates the progression of atherosclerosis in transgenic rabbits. Circulation 2006, 113:1993-2001.
152. Filippov S., Koenig G.C., Chun T.H., Hotary K.B., Ota I., Bugge T.H., et al. MT1-matrix metalloproteinase directs arterial wall invasion and neointima formation by vascular smooth muscle cells. J. Exp. Med. 2005, 202:663-671.
153. Johnson J.L. Matrix metalloproteinases: influence on smooth muscle cells and atherosclerotic plaque stability. Expert. Rev. Cardiovasc. Ther. 2007, 5:265-282.
154. Herrmann J., Lerman L.O., Mukhopadhyay D., Napoli C., Lerman A. Angiogenesis in atherogenesis. Arterioscler. Thromb. Vasc. Biol. 2006, 26:1948-1957.
155. Moreno P.R., Purushothaman K.R., Fuster V., Echeverri D., Truszczynska H., Sharma S.K., et al. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation 2004, 110:2032-2038.
156. Zalba G., Fortuno A., Orbe J., San Jose G., Moreno M.U., Belzunce M., et al. Phagocytic NADPH oxidase-dependent superoxide production stimulates matrix metalloproteinase-9: implications for human atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2007, 27:587-593.
157. Montero I., Orbe J., Varo N., Beloqui O., Monreal J.I., Rodriguez J.A., et al. C-reactive protein induces matrix metalloproteinase-1 and -10 in human endothelial cells: implications for clinical and subclinical atherosclerosis. J. Am. Coll. Cardiol. 2006, 47:1369-1378.
158. Ogata T., Shibamura H., Tromp G., Sinha M., Goddard K.A., Sakalihasan N., et al. Genetic analysis of polymorphisms in biologically relevant candidate genes in patients with abdominal aortic aneurysms. J. Vasc. Surg. 2005, 41:1036-1042.
159. Orbe J., Fernandez L., Rodriguez J.A., Rabago G., Belzunce M., Monasterio A., et al. Different expression of MMPs/TIMP-1 in human atherosclerotic lesions. Relation to plaque features and vascular bed. Atherosclerosis 2003, 170:269-276.
160. Loftus I.M., Naylor A.R., Goodall S., Crowther M., Jones L., Bell P.R., et al. Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption. Stroke 2000, 31:40-47.
161. Vine N., Powell J.T. Metalloproteinases in degenerative aortic disease. Clin. Sci. (Lond.) 1991, 81:233-239.
162. Chen F., Eriksson P., Hansson G.K., Herzfeld I., Klein M., Hansson L.O., et al. Expression of matrix metalloproteinase 9 and its regulators in the unstable coronary atherosclerotic plaque. Int. J. Mol. Med. 2005, 15:57-65.
163. Formato M., Farina M., Spirito R., Maggioni M., Guarino A., Cherchi G.M., et al. Evidence for a proinflammatory and proteolytic environment in plaques from endarterectomy segments of human carotid arteries. Arterioscler. Thromb. Vasc. Biol. 2004, 24:129-135.
164. Luttun A., Lutgens E., Manderveld A., Maris K., Collen D., Carmeliet P., et al. Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth. Circulation 2004, 109:1408-1414.
165. Johnson C., Galis Z.S. Matrix metalloproteinase-2 and -9 differentially regulate smooth muscle cell migration and cell-mediated collagen organization. Arterioscler. Thromb. Vasc. Biol. 2004, 24:54-60.
166. Fabunmi R.P., Baker A.H., Murray E.J., Booth R.F., Newby A.C. Divergent regulation by growth factors and cytokines of 95kDa and 72kDa gelatinases and tissue inhibitors or metalloproteinases-1, -2, and -3 in rabbit aortic smooth muscle cells. Biochem. J. 1996, 315(Pt. 1):335-342.
167. Davies M.J. Reactive oxygen species, metalloproteinases, and plaque stability. Circulation 1998, 97:2382-2383.
168. Papalambros E., Sigala F., Georgopoulos S., Panou N., Kavatzas N., Agapitos M., et al. Vascular endothelial growth factor and matrix metalloproteinase 9 expression in human carotid atherosclerotic plaques: relationship with plaque destabilization via neovascularization. Cerebrovasc. Dis. 2004, 18:160-165.
169. Park J.E., Keller G.A., Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol. Biol. Cell 1993, 4:1317-1326.
170. Davies M.J., Richardson P.D., Woolf N., Katz D.R., Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br. Heart J. 1993, 69:377-381.
171. Kalela A., Koivu T.A., Sisto T., Kanervisto J., Hoyhtya M., Sillanaukee P., et al. Serum matrix metalloproteinase-9 concentration in angiographically assessed coronary artery disease. Scand. J. Clin. Lab. Invest. 2002, 62:337-342.
172. Uzui H., Harpf A., Liu M., Doherty T.M., Shukla A., Chai N.N., et al. Increased expression of membrane type 3-matrix metalloproteinase in human atherosclerotic plaque: role of activated macrophages and inflammatory cytokines. Circulation 2002, 106:3024-3030.
173. Cleutjens J.P., Creemers E.E. Integration of concepts: cardiac extracellular matrix remodeling after myocardial infarction. J. Card. Fail. 2002, 8:S344-S348.
174. Creemers E.E., Cleutjens J.P., Smits J.F., Daemen M.J. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?. Circ. Res. 2001, 89:201-210.
175. Rosell A., Ortega-Aznar A., Alvarez-Sabin J., Fernandez-Cadenas I., Ribo M., Molina C.A., et al. Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. Stroke 2006, 37:1399-1406.
176. Wang X., Lee S.R., Arai K., Tsuji K., Rebeck G.W., Lo E.H. Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat. Med. 2003, 9:1313-1317.
177. Paramo J.A., Orbe J., Fernandez J. Fibrinolysis/proteolysis balance in stable angina pectoris in relation to angiographic findings. Thromb. Haemost. 2001, 86:636-639.
178. Bittner A., Alcaino H., Castro P.F., Perez O., Corbalan R., Troncoso R., et al. Matrix metalloproteinase-9 activity is associated to oxidative stress in patients with acute coronary syndrome. Int. J. Cardiol. 2010, 143:98-100.
179. Brunner S., Kim J.O., Methe H. Relation of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14+ monocytes to progression of coronary artery disease. Am. J. Cardiol. 2010, 105:429-434.
180. Higo S., Uematsu M., Yamagishi M., Ishibashi-Ueda H., Awata M., Morozumi T., et al. Elevation of plasma matrix metalloproteinase-9 in the culprit coronary artery in patients with acute myocardial infarction: clinical evidence from distal protection. Circ. J. 2005, 69:1180-1185.
181. Kelly D., Khan S.Q., Thompson M., Cockerill G., Ng L.L., Samani N., et al. Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction. Eur. Heart J. 2008, 29:2116-2124.
182. Welsh P., Whincup P.H., Papacosta O., Wannamethee S.G., Lennon L., Thomson A., et al. Serum matrix metalloproteinase-9 and coronary heart disease: a prospective study in middle-aged men. QJM 2008, 101:785-791.
183. Gargiulo S., Sottero B., Gamba P., Chiarpotto E., Poli G., Leonarduzzi G. Plaque oxysterols induce unbalanced up-regulation of matrix metalloproteinase-9 in macrophagic cells through redox-sensitive signaling pathways: implications regarding the vulnerability of atherosclerotic lesions. Free Radic. Biol. Med. 2011, 51:844-855.
184. Sundstrom J., Evans J.C., Benjamin E.J., Levy D., Larson M.G., Sawyer D.B., et al. Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: the Framingham heart study. Eur. Heart J. 2004, 25:1509-1516.
185. Sundstrom J., Evans J.C., Benjamin E.J., Levy D., Larson M.G., Sawyer D.B., et al. Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study. Circulation 2004, 109:2850-2856.
186. Koh K.K., Ahn J.Y., Kang M.H., Kim D.S., Jin D.K., Sohn M.S., et al. Effects of hormone replacement therapy on plaque stability, inflammation, and fibrinolysis in hypertensive or overweight postmenopausal women. Am. J. Cardiol. 2001, 88:1423-1426. A1428.
187. Beaudeux J.L., Giral P., Bruckert E., Bernard M., Foglietti M.J., Chapman M.J. Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1 as potential markers of carotid atherosclerosis in infraclinical hyperlipidemia. Atherosclerosis 2003, 169:139-146.
188. Koh K.K., Son J.W., Ahn J.Y., Jin D.K., Kim H.S., Choi Y.M., et al. Comparative effects of diet and statin on NO bioactivity and matrix metalloproteinases in hypercholesterolemic patients with coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 2002, 22:e19-e23.
189. Orbe J., Rodriguez J.A., Arias R., Belzunce M., Nespereira B., Perez-Ilzarbe M., et al. Antioxidant vitamins increase the collagen content and reduce MMP-1 in a porcine model of atherosclerosis: implications for plaque stabilization. Atherosclerosis 2003, 167:45-53.
190. Huang Y., Song L., Wu S., Fan F., Lopes-Virella M.F. Oxidized LDL differentially regulates MMP-1 and TIMP-1 expression in vascular endothelial cells. Atherosclerosis 2001, 156:119-125.
191. Li D., Liu L., Chen H., Sawamura T., Ranganathan S., Mehta J.L. LOX-1 mediates oxidized low-density lipoprotein-induced expression of matrix metalloproteinases in human coronary artery endothelial cells. Circulation 2003, 107:612-617.
192. Nakamura T., Ebihara I., Shimada N., Koide H. Effect of cigarette smoking on plasma metalloproteinase-9 concentration. Clin. Chim. Acta 1998, 276:173-177.
193. Ponomarenko Y., Leo M.A., Kroll W., Lieber C.S. Effects of alcohol consumption on eight circulating markers of liver fibrosis. Alcohol Alcohol. 2002, 37:252-255.
194. Roberts C.K., Won D., Pruthi S., Kurtovic S., Sindhu R.K., Vaziri N.D., et al. Effect of a short-term diet and exercise intervention on oxidative stress, inflammation, MMP-9, and monocyte chemotactic activity in men with metabolic syndrome factors. J. Appl. Physiol. 2006, 100:1657-1665.
195. Death A.K., Fisher E.J., McGrath K.C., Yue D.K. High glucose alters matrix metalloproteinase expression in two key vascular cells: potential impact on atherosclerosis in diabetes. Atherosclerosis 2003, 168:263-269.
196. Marx N., Froehlich J., Siam L., Ittner J., Wierse G., Schmidt A., et al. Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 2003, 23:283-288.
197. Laimer M., Kaser S., Kranebitter M., Sandhofer A., Muhlmann G., Schwelberger H., et al. Effect of pronounced weight loss on the nontraditional cardiovascular risk marker matrix metalloproteinase-9 in middle-aged morbidly obese women. Int. J. Obes. (Lond.) 2005, 29:498-501.
198. Hayden M.R., Sowers J.R., Tyagi S.C. The central role of vascular extracellular matrix and basement membrane remodeling in metabolic syndrome and type 2 diabetes: the matrix preloaded. Cardiovasc. Diabetol. 2005, 4:9.
199. Yasmin, McEniery C.M., Wallace S., Dakham Z., Pulsalkar P., Maki-Petaja K., et al. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler. Thromb. Vasc. Biol. 2005, 25:372.
200. Querejeta R., Lopez B., Gonzalez A., Sanchez E., Larman M., Martinez Ubago J.L., et al. Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis. Circulation 2004, 110:1263-1268.
201. Wagsater D., Zhu C., Bjorkegren J., Skogsberg J., Eriksson P. MMP-2 and MMP-9 are prominent matrix metalloproteinases during atherosclerosis development in the Ldlr(-/-)Apob(100/100) mouse. Int. J. Mol. Med. 2011, 28:247-253.
202. Williams T.N., Zhang C.X., Game B.A., He L., Huang Y. C-reactive protein stimulates MMP-1 expression in U937 histiocytes through Fc[gamma]RII and extracellular signal-regulated kinase pathway: an implication of CRP involvement in plaque destabilization. Arterioscler. Thromb. Vasc. Biol. 2004, 24:61-66.
203. Ferroni P., Basili S., Martini F., Cardarello C.M., Ceci F., Di Franco M., et al. Serum metalloproteinase 9 levels in patients with coronary artery disease: a novel marker of inflammation. J. Investig. Med. 2003, 51:295-300.
204. Falk E., Shah P.K., Fuster V. Coronary plaque disruption. Circulation 1995, 92:657-671.
205. Burke A.P., Farb A., Malcom G.T., Liang Y.H., Smialek J., Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N. Engl. J. Med. 1997, 336:1276-1282.
206. van der Wal A.C., Becker A.E., van der Loos C.M., Das P.K. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994, 89:36-44.
207. Davies M.J., Thomas A. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N. Engl. J. Med. 1984, 310:1137-1140.
208. Kai H., Ikeda H., Yasukawa H., Kai M., Seki Y., Kuwahara F., et al. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J. Am. Coll. Cardiol. 1998, 32:368-372.
209. Rajagopalan S., Meng X.P., Ramasamy S., Harrison D.G., Galis Z.S. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J. Clin. Invest. 1996, 98:2572-2579.
210. Sukhova G.K., Schonbeck U., Rabkin E., Schoen F.J., Poole A.R., Billinghurst R.C., et al. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation 1999, 99:2503-2509.
211. Galis Z.S., Kranzhofer R., Fenton J.W., Libby P. Thrombin promotes activation of matrix metalloproteinase-2 produced by cultured vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 1997, 17:483-489.
212. Lindstedt K.A., Kovanen P.T. Mast cells in vulnerable coronary plaques: potential mechanisms linking mast cell activation to plaque erosion and rupture. Curr. Opin. Lipidol. 2004, 15:567-573.
213. Sawicki G., Salas E., Murat J., Miszta-Lane H., Radomski M.W. Release of gelatinase A during platelet activation mediates aggregation. Nature 1997, 386:616-619.
214. Rajavashisth T.B., Liao J.K., Galis Z.S., Tripathi S., Laufs U., Tripathi J., et al. Inflammatory cytokines and oxidized low density lipoproteins increase endothelial cell expression of membrane type 1-matrix metalloproteinase. J. Biol. Chem. 1999, 274:11924-11929.
215. Carmeliet P., Moons L., Dewerchin M., Mackman N., Luther T., Breier G., et al. Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system. Ann. N. Y. Acad. Sci. 1997, 811:191-206.
216. Carmeliet P., Moons L., Lijnen R., Baes M., Lemaitre V., Tipping P., et al. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat. Genet. 1997, 17:439-444.
217. Sluijter J.P., Pulskens W.P., Schoneveld A.H., Velema E., Strijder C.F., Moll F., et al. Matrix metalloproteinase 2 is associated with stable and matrix metalloproteinases 8 and 9 with vulnerable carotid atherosclerotic lesions: a study in human endarterectomy specimen pointing to a role for different extracellular matrix metalloproteinase inducer glycosylation forms. Stroke 2006, 37:235-239.
218. Newby A.C. Metalloproteinases and vulnerable atherosclerotic plaques. Trends Cardiovasc. Med. 2007, 17:253-258.
219. Herman M.P., Sukhova G.K., Libby P., Gerdes N., Tang N., Horton D.B., et al. Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation 2001, 104:1899-1904.
220. Mach F., Schonbeck U., Fabunmi R.P., Murphy C., Atkinson E., Bonnefoy J.Y., et al. T lymphocytes induce endothelial cell matrix metalloproteinase expression by a CD40L-dependent mechanism: implications for tubule formation. Am. J. Pathol. 1999, 154:229-238.
221. Schonbeck U., Mach F., Sukhova G.K., Atkinson E., Levesque E., Herman M., et al. Expression of stromelysin-3 in atherosclerotic lesions: regulation via CD40-CD40 ligand signaling in vitro and in vivo. J. Exp. Med. 1999, 189:843-853.
222. Lee E., Grodzinsky A.J., Libby P., Clinton S.K., Lark M.W., Lee R.T. Human vascular smooth muscle cell-monocyte interactions and metalloproteinase secretion in culture. Arterioscler. Thromb. Vasc. Biol. 1995, 15:2284-2289.
223. Sasaguri T., Arima N., Tanimoto A., Shimajiri S., Hamada T., Sasaguri Y. A role for interleukin 4 in production of matrix metalloproteinase 1 by human aortic smooth muscle cells. Atherosclerosis 1998, 138:247-253.
224. Schonbeck U., Mach F., Sukhova G.K., Murphy C., Bonnefoy J.Y., Fabunmi R.P., et al. Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes: a role for CD40 signaling in plaque rupture?. Circ. Res. 1997, 81:448-454.
225. Fabunmi R.P., Sukhova G.K., Sugiyama S., Libby P. Expression of tissue inhibitor of metalloproteinases-3 in human atheroma and regulation in lesion-associated cells: a potential protective mechanism in plaque stability. Circ. Res. 1998, 83:270-278.
226. Rajavashisth T.B., Xu X.P., Jovinge S., Meisel S., Xu X.O., Chai N.N., et al. Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques: evidence for activation by proinflammatory mediators. Circulation 1999, 99:3103-3109.
227. Shipley J.M., Wesselschmidt R.L., Kobayashi D.K., Ley T.J., Shapiro S.D. Metalloelastase is required for macrophage-mediated proteolysis and matrix invasion in mice. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:3942-3946.
228. Hojo Y., Ikeda U., Takahashi M., Sakata Y., Takizawa T., Okada K., et al. Matrix metalloproteinase-1 expression by interaction between monocytes and vascular endothelial cells. J. Mol. Cell. Cardiol. 2000, 32:1459-1468.
229. Cheung P.Y., Sawicki G., Wozniak M., Wang W., Radomski M.W., Schulz R. Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation 2000, 101:1833-1839.
230. Inokubo Y., Hanada H., Ishizaka H., Fukushi T., Kamada T., Okumura K. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am. Heart J. 2001, 141:211-217.
231. Hirohata S., Kusachi S., Murakami M., Murakami T., Sano I., Watanabe T., et al. Time dependent alterations of serum matrix metalloproteinase-1 and metalloproteinase-1 tissue inhibitor after successful reperfusion of acute myocardial infarction. Heart 1997, 78:278-284.
232. Hojo Y., Ikeda U., Ueno S., Arakawa H., Shimada K. Expression of matrix metalloproteinases in patients with acute myocardial infarction. Jpn. Circ. J. 2001, 65:71-75.
233. Forough R., Koyama N., Hasenstab D., Lea H., Clowes M., Nikkari S.T., et al. Overexpression of tissue inhibitor of matrix metalloproteinase-1 inhibits vascular smooth muscle cell functions in vitro and in vivo. Circ. Res. 1996, 79:812-820.
234. Bendeck M.P., Zempo N., Clowes A.W., Galardy R.E., Reidy M.A. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ. Res. 1994, 75:539-545.
235. Zempo N., Kenagy R.D., Au Y.P., Bendeck M., Clowes M.M., Reidy M.A., et al. Matrix metalloproteinases of vascular wall cells are increased in balloon-injured rat carotid artery. J. Vasc. Surg. 1994, 20:209-217.
236. Tavakoli S., Razavian M., Zhang J., Nie L., Marfatia R., Dobrucki L.W., et al. Matrix metalloproteinase activation predicts amelioration of remodeling after dietary modification in injured arteries. Arterioscler. Thromb. Vasc. Biol. 2011, 31:102-109.
237. Bassiouny H.S., Song R.H., Hong X.F., Singh A., Kocharyan H., Glagov S. Flow regulation of 72-kD collagenase IV (MMP-2) after experimental arterial injury. Circulation 1998, 98:157-163.
238. Godin D., Ivan E., Johnson C., Magid R., Galis Z.S. Remodeling of carotid artery is associated with increased expression of matrix metalloproteinases in mouse blood flow cessation model. Circulation 2000, 102:2861-2866.
239. Abbruzzese T.A., Guzman R.J., Martin R.L., Yee C., Zarins C.K., Dalman R.L. Matrix metalloproteinase inhibition limits arterial enlargements in a rodent arteriovenous fistula model. Surgery 1998, 124:328-334. discussion 334-325.
240. Chesler N.C., Ku D.N., Galis Z.S. Transmural pressure induces matrix-degrading activity in porcine arteries ex vivo. Am. J. Physiol. 1999, 277:H2002-H2009.
241. Southgate K.M., Mehta D., Izzat M.B., Newby A.C., Angelini G.D. Increased secretion of basement membrane-degrading metalloproteinases in pig saphenous vein into carotid artery interposition grafts. Arterioscler. Thromb. Vasc. Biol. 1999, 19:1640-1649.
242. Mavromatis K., Fukai T., Tate M., Chesler N., Ku D.N., Galis Z.S. Early effects of arterial hemodynamic conditions on human saphenous veins perfused ex vivo. Arterioscler. Thromb. Vasc. Biol. 2000, 20:1889-1895.
243. Rudic R.D., Shesely E.G., Maeda N., Smithies O., Segal S.S., Sessa W.C. Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling. J. Clin. Invest. 1998, 101:731-736.
244. Lafont A., Durand E., Samuel J.L., Besse B., Addad F., Levy B.I., et al. Endothelial dysfunction and collagen accumulation: two independent factors for restenosis and constrictive remodeling after experimental angioplasty. Circulation 1999, 100:1109-1115.
245. Tronc F., Mallat Z., Lehoux S., Wassef M., Esposito B., Tedgui A. Role of matrix metalloproteinases in blood flow-induced arterial enlargement: interaction with NO. Arterioscler. Thromb. Vasc. Biol. 2000, 20:E120-E126.
246. Cai H., Harrison D.G. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ. Res. 2000, 87:840-844.
247. Frears E.R., Zhang Z., Blake D.R., O'Connell J.P., Winyard P.G. Inactivation of tissue inhibitor of metalloproteinase-1 by peroxynitrite. FEBS Lett. 1996, 381:21-24.
248. Libby P., Galis Z.S. Cytokines regulate genes involved in atherogenesis. Ann. N. Y. Acad. Sci. 1995, 748:158-168. discussion 168-170.
249. Rekhter M.D., Hicks G.W., Brammer D.W., Hallak H., Kindt E., Chen J., et al. Hypercholesterolemia causes mechanical weakening of rabbit atheroma: local collagen loss as a prerequisite of plaque rupture. Circ. Res. 2000, 86:101-108.
250. Johnson J.L., Jackson C.L., Angelini G.D., George S.J. Activation of matrix-degrading metalloproteinases by mast cell proteases in atherosclerotic plaques. Arterioscler. Thromb. Vasc. Biol. 1998, 18:1707-1715.
251. Tauth J., Pinnow E., Sullebarger J.T., Basta L., Gursoy S., Lindsay J., et al. Predictors of coronary arterial remodeling patterns in patients with myocardial ischemia. Am. J. Cardiol. 1997, 80:1352-1355.
252. Sudhir K., Ports T.A., Amidon T.M., Goldberger J.J., Bhushan V., Kane J.P., et al. Increased prevalence of coronary ectasia in heterozygous familial hypercholesterolemia. Circulation 1995, 91:1375-1380.
253. Galis Z.S., Asanuma K., Godin D., Meng X. N-acetyl-cysteine decreases the matrix-degrading capacity of macrophage-derived foam cells: new target for antioxidant therapy?. Circulation 1998, 97:2445-2453.
254. Aikawa M., Rabkin E., Okada Y., Voglic S.J., Clinton S.K., Brinckerhoff C.E., et al. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. Circulation 1998, 97:2433-2444.
255. Bellosta S., Via D., Canavesi M., Pfister P., Fumagalli R., Paoletti R., et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler. Thromb. Vasc. Biol. 1998, 18:1671-1678.
256. Ikeda U., Shimpo M., Ohki R., Inaba H., Takahashi M., Yamamoto K., et al. Fluvastatin inhibits matrix metalloproteinase-1 expression in human vascular endothelial cells. Hypertension 2000, 36:325-329.
257. James T.W., Wagner R., White L.A., Zwolak R.M., Brinckerhoff C.E. Induction of collagenase and stromelysin gene expression by mechanical injury in a vascular smooth muscle-derived cell line. J. Cell. Physiol. 1993, 157:426-437.
258. Southgate K.M., Fisher M., Banning A.P., Thurston V.J., Baker A.H., Fabunmi R.P., et al. Upregulation of basement membrane-degrading metalloproteinase secretion after balloon injury of pig carotid arteries. Circ. Res. 1996, 79:1177-1187.
259. Cheng L., Mantile G., Pauly R., Nater C., Felici A., Monticone R., et al. Adenovirus-mediated gene transfer of the human tissue inhibitor of metalloproteinase-2 blocks vascular smooth muscle cell invasiveness in vitro and modulates neointimal development in vivo. Circulation 1998, 98:2195-2201.
260. Hojo Y., Ikeda U., Katsuki T., Mizuno O., Fujikawa H., Shimada K. Matrix metalloproteinase expression in the coronary circulation induced by coronary angioplasty. Atherosclerosis 2002, 161:185-192.
261. Brown D.L., Hibbs M.S., Kearney M., Isner J.M. Differential expression of 92-kDa gelatinase in primary atherosclerotic versus restenotic coronary lesions. Am. J. Cardiol. 1997, 79:878-882.
262. Lehoux S., Lemarie C.A., Esposito B., Lijnen H.R., Tedgui A. Pressure-induced matrix metalloproteinase-9 contributes to early hypertensive remodeling. Circulation 2004, 109:1041-1047.
263. Basalyga D.M., Simionescu D.T., Xiong W., Baxter B.T., Starcher B.C., Vyavahare N.R. Elastin degradation and calcification in an abdominal aorta injury model: role of matrix metalloproteinases. Circulation 2004, 110:3480-3487.
264. Johnson J.L., Dwivedi A., Somerville M., George S.J., Newby A.C. Matrix metalloproteinase (MMP)-3 activates MMP-9 mediated vascular smooth muscle cell migration and neointima formation in mice. Arterioscler. Thromb. Vasc. Biol. 2011, 31:e35-e44.
265. Johnson C., Sung H.J., Lessner S.M., Fini M.E., Galis Z.S. Matrix metalloproteinase-9 is required for adequate angiogenic revascularization of ischemic tissues: potential role in capillary branching. Circ. Res. 2004, 94:262-268.
266. Chun T.H., Sabeh F., Ota I., Murphy H., McDonagh K.T., Holmbeck K., et al. MT1-MMP-dependent neovessel formation within the confines of the three-dimensional extracellular matrix. J. Cell Biol. 2004, 167:757-767.
267. Lijnen H.R., Van Hoef B., Vanlinthout I., Verstreken M., Rio M.C., Collen D. Accelerated neointima formation after vascular injury in mice with stromelysin-3 (MMP-11) gene inactivation. Arterioscler. Thromb. Vasc. Biol. 1999, 19:2863-2870.
268. Silence J., Lupu F., Collen D., Lijnen H.R. Persistence of atherosclerotic plaque but reduced aneurysm formation in mice with stromelysin-1 (MMP-3) gene inactivation. Arterioscler. Thromb. Vasc. Biol. 2001, 21:1440-1445.
269. Xiao Q., Zhang F., Lin L., Fang C., Wen G., Tsai T.N., et al. Functional role of matrix metalloproteinase-8 in stem/progenitor cell migration and their recruitment into atherosclerotic lesions. Circ. Res. 2013, 112:35-47.
270. Silence J., Collen D., Lijnen H.R. Reduced atherosclerotic plaque but enhanced aneurysm formation in mice with inactivation of the tissue inhibitor of metalloproteinase-1 (TIMP-1) gene. Circ. Res. 2002, 90:897-903.
271. Lemaitre V., Soloway P.D., D'Armiento J. Increased medial degradation with pseudo-aneurysm formation in apolipoprotein E-knockout mice deficient in tissue inhibitor of metalloproteinases-1. Circulation 2003, 107:333-338.
272. Galis Z.S., Johnson C., Godin D., Magid R., Shipley J.M., Senior R.M., et al. Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. Circ. Res. 2002, 91:852-859.
273. Cho A., Reidy M.A. Matrix metalloproteinase-9 is necessary for the regulation of smooth muscle cell replication and migration after arterial injury. Circ. Res. 2002, 91:845-851.
274. Lovdahl C., Thyberg J., Cercek B., Blomgren K., Dimayuga P., Kallin B., et al. Antisense oligonucleotides to stromelysin mRNA inhibit injury-induced proliferation of arterial smooth muscle cells. Histol. Histopathol. 1999, 14:1101-1112.
275. Shi W., Brown M.D., Wang X., Wong J., Kallmes D.F., Matsumoto A.H., et al. Genetic backgrounds but not sizes of atherosclerotic lesions determine medial destruction in the aortic root of apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2003, 23:1901-1906.
276. Johnson J.L., George S.J., Newby A.C., Jackson C.L. Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:15575-15580.
277. Ikonomidis J.S., Barbour J.R., Amani Z., Stroud R.E., Herron A.R., McClister D.M., et al. Effects of deletion of the matrix metalloproteinase 9 gene on development of murine thoracic aortic aneurysms. Circulation 2005, 112:I242-I248.
278. Rouis M., Adamy C., Duverger N., Lesnik P., Horellou P., Moreau M., et al. Adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-1 reduces atherosclerotic lesions in apolipoprotein E-deficient mice. Circulation 1999, 100:533-540.
279. Allaire E., Forough R., Clowes M., Starcher B., Clowes A.W. Local overexpression of TIMP-1 prevents aortic aneurysm degeneration and rupture in a rat model. J. Clin. Invest. 1998, 102:1413-1420.
280. Lemaitre V., Kim H.E., Forney-Prescott M., Okada Y., D'Armiento J. Transgenic expression of matrix metalloproteinase-9 modulates collagen deposition in a mouse model of atherosclerosis. Atherosclerosis 2009, 205:107-112.
281. Girelli D., Martinelli N., Peyvandi F., Olivieri O. Genetic architecture of coronary artery disease in the genome-wide era: implications for the emerging "golden dozen" loci. Semin. Thromb. Hemost. 2009, 35:671-682.
282. Lusis A.J. Genetic factors in cardiovascular disease. 10 questions. Trends Cardiovasc. Med. 2003, 13:309-316.
283. Ye S., Gale C.R., Martyn C.N. Variation in the matrix metalloproteinase-1 gene and risk of coronary heart disease. Eur. Heart J. 2003, 24:1668-1671.
284. Nojiri T., Morita H., Imai Y., Maemura K., Ohno M., Ogasawara K., et al. Genetic variations of matrix metalloproteinase-1 and -3 promoter regions and their associations with susceptibility to myocardial infarction in Japanese. Int. J. Cardiol. 2003, 92:181-186.
285. Ghaderian S.M., Akbarzadeh Najar R., Tabatabaei Panah A.S. Genetic polymorphisms and plasma levels of matrix metalloproteinases and their relationships with developing acute myocardial infarction. Coron. Artery Dis. 2010, 21:330-335.
286. Roman-Garcia P., Coto E., Reguero J.R., Cannata-Andia J.B., Lozano I., Avanzas P., et al. Matrix metalloproteinase 1 promoter polymorphisms and risk of myocardial infarction: a case-control study in a Spanish population. Coron. Artery Dis. 2009, 20:383-386.
287. Sakowicz A., Fendler W., Lelonek M., Pietrucha T. Genetic variability and the risk of myocardial infarction in Poles under 45 years of age. Arch. Med. Sci. 2010, 6:160-167.
288. Horne B.D., Camp N.J., Carlquist J.F., Muhlestein J.B., Kolek M.J., Nicholas Z.P., et al. Multiple-polymorphism associations of 7 matrix metalloproteinase and tissue inhibitor metalloproteinase genes with myocardial infarction and angiographic coronary artery disease. Am. Heart J. 2007, 154:751-758.
289. Niu W., Qi Y. Matrix metalloproteinase family gene polymorphisms and risk for coronary artery disease: systematic review and meta-analysis. Heart 2012, 98:1483-1491.
290. Alp E., Menevse S., Tulmac M., Yilmaz A., Yalcin R., Cengel A. The role of matrix metalloproteinase-2 promoter polymorphisms in coronary artery disease and myocardial infarction. Genet. Test Mol. Biomarkers 2011, 15:193-202.
291. Mishra A., Srivastava A., Mittal T., Garg N., Mittal B. Association of matrix metalloproteinases (MMP2, MMP7 and MMP9) genetic variants with left ventricular dysfunction in coronary artery disease patients. Clin. Chim. Acta 2012, 413:1668-1674.
292. Perez-Hernandez N., Vargas-Alarcon G., Martinez-Rodriguez N., Martinez-Rios M.A., Pena-Duque M.A., Pena-Diaz Ade L., et al. The matrix metalloproteinase 2-1575 gene polymorphism is associated with the risk of developing myocardial infarction in Mexican patients. J. Atheroscler. Thromb. 2012, 19:718-727.
293. Delgado-Enciso I., Gonzalez-Hernandez N.A., Baltazar-Rodriguez L.M., Millan-Guerrero R.O., Newton-Sanchez O., Bayardo-Noriega A., et al. Association of matrix metalloproteinase-2 gene promoter polymorphism with myocardial infarction susceptibility in a Mexican population. J. Genet. 2009, 88:249-252.
294. Wu N., Lu X., Hua Y., Song L., Ye J., Li J., et al. Haplotype analysis of the stromelysin-1 (MMP3) and gelatinase B (MMP9) genes in relation to coronary heart disease. Ann. Hum. Genet. 2009, 73:404-410.
295. Zhou X., Huang J., Chen J., Su S., Chen R., Gu D. Haplotype analysis of the matrix metalloproteinase 3 gene and myocardial infarction in a Chinese Han population. The Beijing atherosclerosis study. Thromb. Haemost. 2004, 92:867-873.
296. Abilleira S., Bevan S., Markus H.S. The role of genetic variants of matrix metalloproteinases in coronary and carotid atherosclerosis. J. Med. Genet. 2006, 43:897-901.
297. Wu H.D., Bai X., Chen D.M., Cao H.Y., Qin L. Association of genetic polymorphisms in matrix metalloproteinase-9 and coronary artery disease in the chinese han population: a case-control study. Genet. Test Mol. Biomarkers 2013, 17:707-712.
298. Spurthi K.M., Galimudi R.K., Srilatha G., Sahu S.K., Nallari P., Hanumanth S.R. Influence of gelatinase B polymorphic variants and its serum levels in atherosclerosis. Genet. Test Mol. Biomarkers 2012, 16:850-854.
299. Opstad T.B., Pettersen A.A., Weiss T.W., Akra S., Ovstebo R., Arnesen H., et al. Genetic variation, gene-expression and circulating levels of matrix metalloproteinase-9 in patients with stable coronary artery disease. Clin. Chim. Acta 2012, 413:113-120.
300. Wang L., Ma Y.T., Xie X., Yang Y.N., Fu Z.Y., Li X.M., et al. Interaction between MMP-9 gene polymorphisms and smoking in relation to myocardial infarction in a Uighur population. Clin. Appl. Thromb. Hemost. 2012, 18:72-78.
301. Saedi M., Vaisi-Raygani A., Khaghani S., Shariftabrizi A., Rezaie M., Pasalar P., et al. Matrix metalloproteinase-9 functional promoter polymorphism 1562C>T increased risk of early-onset coronary artery disease. Mol. Biol. Rep. 2012, 39:555-562.
302. Wang L., Ma Y.T., Xie X., Yang Y.N., Fu Z.Y., Liu F., et al. Association of MMP9 gene -1562 C/T polymorphism with myocardial infarction in Uighur population of Xinjiang. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2011, 28:180-184.
303. Haberbosch W., Gardemann A. Gelatinase B C(-1562)T polymorphism in relation to ischaemic heart disease. Scand. J. Clin. Lab. Invest. 2005, 65:513-522.
304. Zhi H., Wang H., Ren L., Shi Z., Peng H., Cui L., et al. Functional polymorphisms of matrix metallopeptidase-9 and risk of coronary artery disease in a Chinese population. Mol. Biol. Rep. 2010, 37:13-20.
305. Fallah S., Seifi M., Ghasemi A., Firoozrai M., Samadikuchaksaraei A. Matrix metalloproteinase-9 and paraoxonase 1 Q/R192 gene polymorphisms and the risk of coronary artery stenosis in Iranian subjects. J. Clin. Lab. Anal. 2010, 24:305-310.
306. Li J., Lu H., Tao F., Zhou H., Feng G., He L., et al. Meta-analysis of MMP9-562C/T and the risk of coronary heart disease. Cardiology 2013, 124:53-59.
307. Jguirim-Souissi I., Jelassi A., Slimani A., Addad F., Hassine M., Hamda K.B., et al. Matrix metalloproteinase-1 and matrix metalloproteinase-12 gene polymorphisms and the outcome of coronary artery disease. Coron. Artery Dis. 2011, 22:388-393.
308. Lamblin N., Bauters C., Hermant X., Lablanche J.M., Helbecque N., Amouyel P. Polymorphisms in the promoter regions of MMP-2, MMP-3, MMP-9 and MMP-12 genes as determinants of aneurysmal coronary artery disease. J. Am. Coll. Cardiol. 2002, 40:43-48.
309. Vasku A., Meluzin J., Blahak J., Kincl V., Goldbergova M.P., Sitar J., et al. Matrix metalloproteinase 13 genotype in rs640198 polymorphism is associated with severe coronary artery disease. Dis. Markers 2012, 33:43-49.
310. Vasku A., Goldbergova M., Holla L.I., Spinarova L., Spinar J., Vitovec J., et al. Two MMP-2 promoter polymorphisms (-790T/G and -735C/T) in chronic heart failure. Clin. Chem. Lab. Med. 2003, 41:1299-1303.
311. Hlatky M.A., Ashley E., Quertermous T., Boothroyd D.B., Ridker P., Southwick A., et al. Matrix metalloproteinase circulating levels, genetic polymorphisms, and susceptibility to acute myocardial infarction among patients with coronary artery disease. Am. Heart J. 2007, 154:1043-1051.
312. Davies M.J. Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation 1996, 94:2013-2020.
313. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995, 91:2844-2850.
314. de Maat M.P., Jukema J.W., Ye S., Zwinderman A.H., Moghaddam P.H., Beekman M., et al. Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis. Am. J. Cardiol. 1999, 83:852-856.
315. Ye S., Watts G.F., Mandalia S., Humphries S.E., Henney A.M. Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. Br. Heart J. 1995, 73:209-215.
316. Hirashiki A., Yamada Y., Murase Y., Suzuki Y., Kataoka H., Morimoto Y., et al. Association of gene polymorphisms with coronary artery disease in low- or high-risk subjects defined by conventional risk factors. J. Am. Coll. Cardiol. 2003, 42:1429-1437.
317. Beyzade S., Zhang S., Wong Y.K., Day I.N., Eriksson P., Ye S. Influences of matrix metalloproteinase-3 gene variation on extent of coronary atherosclerosis and risk of myocardial infarction. J. Am. Coll. Cardiol. 2003, 41:2130-2137.
318. Schwarz A., Haberbosch W., Tillmanns H., Gardemann A. The stromelysin-1 5A/6A promoter polymorphism is a disease marker for the extent of coronary heart disease. Dis. Markers 2002, 18:121-128.
319. Liu P.Y., Chen J.H., Li Y.H., Wu H.L., Shi G.Y. Synergistic effect of stromelysin-1 (matrix metallo-proteinase-3) promoter 5A/6A polymorphism with smoking on the onset of young acute myocardial infarction. Thromb. Haemost. 2003, 90:132-139.
320. Terashima M., Akita H., Kanazawa K., Inoue N., Yamada S., Ito K., et al. Stromelysin promoter 5A/6A polymorphism is associated with acute myocardial infarction. Circulation 1999, 99:2717-2719.
321. Humphries S.E., Martin S., Cooper J., Miller G. Interaction between smoking and the stromelysin-1 (MMP3) gene 5A/6A promoter polymorphism and risk of coronary heart disease in healthy men. Ann. Hum. Genet. 2002, 66:343-352.
322. McGlinchey P.G., Spence M.S., Patterson C.C., Allen A.R., Murphy G., Fogarty D., et al. The matrix metalloproteinase-3 (MMP-3) 5A/6A promoter polymorphism is not associated with ischaemic heart disease: analysis employing a family based approach. Dis. Markers 2004, 20:289-294.
323. Zhang B., Ye S., Herrmann S.M., Eriksson P., de Maat M., Evans A., et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 1999, 99:1788-1794.
324. Pollanen P.J., Karhunen P.J., Mikkelsson J., Laippala P., Perola M., Penttila A., et al. Coronary artery complicated lesion area is related to functional polymorphism of matrix metalloproteinase 9 gene: an autopsy study. Arterioscler. Thromb. Vasc. Biol. 2001, 21:1446-1450.
325. Cho H.J., Chae I.H., Park K.W., Ju J.R., Oh S., Lee M.M., et al. Functional polymorphism in the promoter region of the gelatinase B gene in relation to coronary artery disease and restenosis after percutaneous coronary intervention. J. Hum. Genet. 2002, 47:88-91.
326. Wang J., Warzecha D., Wilcken D., Wang X.L. Polymorphism in the gelatinase B gene and the severity of coronary arterial stenosis. Clin. Sci. (Lond.) 2001, 101:87-92.
327. Mittal B., Mishra A., Srivastava A., Garg N. Emerging role of genetic variants of matrix metalloproteinases genes in left ventricular dysfunction. Advances in Biochemistry in Health and Disease 2014, 8:321-334. Springer, New York. S.D. Chakraborti, S. Naranjan (Eds.).
328. Li M., Shi J., Fu L., Wang H., Zhou B., Wu X. Genetic polymorphism of MMP family and coronary disease susceptibility: a meta-analysis. Gene 2012, 495:36-41.
329. Mintz G.S., Popma J.J., Pichard A.D., Kent K.M., Satler L.F., Wong C., et al. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation 1996, 94:35-43.
330. Humphries S., Bauters C., Meirhaeghe A., Luong L., Bertrand M., Amouyel P. The 5A6A polymorphism in the promoter of the stromelysin-1 (MMP3) gene as a risk factor for restenosis. Eur. Heart J. 2002, 23:721-725.
331. Hoppmann P., Koch W., Schomig A., Kastrati A. The 5A/6A polymorphism of the stromelysin-1 gene and restenosis after percutaneous coronary interventions. Eur. Heart J. 2004, 25:335-341.
332. Verschuren J.J., Sampietro M.L., Pons D., Trompet S., Ewing M.M., Quax P.H., et al. Matrix metalloproteinases 2 and 3 gene polymorphisms and the risk of target vessel revascularization after percutaneous coronary intervention: is there still room for determining genetic variation of MMPs for assessment of an increased risk of restenosis?. Dis. Markers 2010, 29:265-273.
333. Pitt B., Byington R.P., Furberg C.D., Hunninghake D.B., Mancini G.B., Miller M.E., et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000, 102:1503-1510.
334. Gomez-Hernandez A., Sanchez-Galan E., Ortego M., Martin-Ventura J.L., Blanco-Colio L.M., Tarin-Vicente N., et al. Effect of intensive atorvastatin therapy on prostaglandin E2 levels and metalloproteinase-9 activity in the plasma of patients with non-ST-elevation acute coronary syndrome. Am. J. Cardiol. 2008, 102:12-18.
335. Fukumoto Y., Libby P., Rabkin E., Hill C.C., Enomoto M., Hirouchi Y., et al. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation 2001, 103:993-999.
336. Tayebjee M.H., Tan K.T., MacFadyen R.J., Lip G.Y. Abnormal circulating levels of metalloprotease 9 and its tissue inhibitor 1 in angiographically proven peripheral arterial disease: relationship to disease severity. J. Intern. Med. 2005, 257:110-116.
337. Herbette L.G., Gaviraghi G., Tulenko T., Mason R.P. Molecular interaction between lacidipine and biological membranes. J. Hypertens. Suppl. 1993, 11:S13-S19.
338. Jorgensen B., Simonsen S., Endresen K., Forfang K., Vatne K., Hansen J., et al. Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: results from the Coronary AngioPlasty Amlodipine REStenosis Study (CAPARES). J. Am. Coll. Cardiol. 2000, 35:592-599.
339. George S.J., Johnson J.L., Angelini G.D., Newby A.C., Baker A.H. Adenovirus-mediated gene transfer of the human TIMP-1 gene inhibits smooth muscle cell migration and neointimal formation in human saphenous vein. Hum. Gene Ther. 1998, 9:867-877.
340. Wilson E.M., Moainie S.L., Baskin J.M., Lowry A.S., Deschamps A.M., Mukherjee R., et al. Region- and type-specific induction of matrix metalloproteinases in post-myocardial infarction remodeling. Circulation 2003, 107:2857-2863.
341. Johnson J.L., Baker A.H., Oka K., Chan L., Newby A.C., Jackson C.L., et al. Suppression of atherosclerotic plaque progression and instability by tissue inhibitor of metalloproteinase-2: involvement of macrophage migration and apoptosis. Circulation 2006, 113:2435-2444.
342. Longo G.M., Xiong W., Greiner T.C., Zhao Y., Fiotti N., Baxter B.T. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J. Clin. Invest. 2002, 110:625-632.
343. Lindholt J.S., Vammen S., Fasting H., Henneberg E.W., Heickendorff L. The plasma level of matrix metalloproteinase 9 may predict the natural history of small abdominal aortic aneurysms. A preliminary study. Eur. J. Vasc. Endovasc. Surg. 2000, 20:281-285.
344. Orbe J., Montero I., Rodriguez J.A., Beloqui O., Roncal C., Paramo J.A. Independent association of matrix metalloproteinase-10, cardiovascular risk factors and subclinical atherosclerosis. J. Thromb. Haemost. 2007, 5:91-97.